|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2007-10-2
|
|
pubmed:abstractText |
To determine the incidence and clinical effects of antibodies that develop during treatment with natalizumab.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1526-632X
|
|
pubmed:author |
pubmed-author:AFFIRM and SENTINEL Investigators,
pubmed-author:CalabresiP APA,
pubmed-author:ConfavreuxCC,
pubmed-author:GalettaS LSL,
pubmed-author:GiovannoniGG,
pubmed-author:HavrdovaEE,
pubmed-author:HutchinsonMM,
pubmed-author:KapposLL,
pubmed-author:LublinF DFD,
pubmed-author:LynnFF,
pubmed-author:MillerD HDH,
pubmed-author:O'ConnorP WPW,
pubmed-author:PanzaraM AMA,
pubmed-author:PhillipsJ TJT,
pubmed-author:PolmanC HCH,
pubmed-author:RadueE-WEW,
pubmed-author:RudickR ARA,
pubmed-author:StuartW HWH,
pubmed-author:WajgtAA,
pubmed-author:Weinstock-GuttmanBB,
pubmed-author:WynnD RDR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1391-403
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17761550-Antibodies, Blocking,
pubmed-meshheading:17761550-Antibodies, Monoclonal,
pubmed-meshheading:17761550-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17761550-Antibody Specificity,
pubmed-meshheading:17761550-Brain,
pubmed-meshheading:17761550-Disability Evaluation,
pubmed-meshheading:17761550-Double-Blind Method,
pubmed-meshheading:17761550-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:17761550-Flow Cytometry,
pubmed-meshheading:17761550-Humans,
pubmed-meshheading:17761550-Interferon-beta,
pubmed-meshheading:17761550-Magnetic Resonance Imaging,
pubmed-meshheading:17761550-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:17761550-Placebo Effect,
pubmed-meshheading:17761550-Recurrence,
pubmed-meshheading:17761550-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
|
|
pubmed:affiliation |
Johns Hopkins Multiple Sclerosis Center, Baltimore, MD, USA. Calabresi@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
